Genomics
Driving the Genomic Era of Drug Development

At a time when predictive and precision medicine has moved from aspiration to critical importance, Genomics—a biotechnology research company—is driving the shift to make these advancements the new standard in healthcare and life sciences.

Founded in Oxford and rapidly expanding to other key hubs like Cambridge, London and even overseas in the U.S., Genomics has become a frontrunner in the global quest to unlock the potential of genomics to help people live healthier, longer lives.

Its advanced statistical analysis platform harnesses powerful algorithms and a vast genome-phenome database, providing pharmaceutical companies with critical insights into genetic variation and its connection to human diseases. Augmented with cutting-edge AI and ML tools, this platform delivers quick, deep analyses that identify diseases’ causes and consequences. By maintaining one of the world’s most comprehensive genotype-phenotype databases, Genomics supports rapid and effective decision-making across all therapeutic areas, fundamentally enhancing drug R&D and the development of targeted, personalised treatments. Such robust infrastructure empowers it to drive significant medical breakthroughs and meet unmet medical needs effectively.

“We guide our partners in securing the path to first-in-class and best-in-class products, expanding current indications, accelerating drug target discovery, and enabling more precise, successful clinical trials,” says Alexandra Fish, Director of Discovery in Life Sciences.

A major highlight of Genomics’ offerings is its genetic risk technology, which empowers clients to assess individual genetic risks and design safer, de-risked clinical trials, ensuring higher success rates and improved patient safety. By addressing risks at the genetic level, Genomics supports its clients in creating more robust trial designs and advancing innovation in drug development.

We guide our partners in securing the path to first-in-class and best-in-class products, accelerating drug target discovery, expanding current indications and enabling more precise, successful clinical trials.

This same spirit of innovation flows into how Genomics helps clients reimagine and expand the value of their existing drug portfolios through target discovery. Drawing on its deep expertise in target intelligence and data analytics, the company uncovers new therapeutic possibilities for existing drugs while refining their safety profiles. Additionally, Genomics supports novel target discovery efforts, using leading AI/ML based methodology. This dual focus—on advancing trial safety and optimising portfolio potential—forms a cohesive strategy that pushes the boundaries of what’s possible in personalised medicine. On the horizon for the company is a novel solution for life sciences clients that will supercharge their drug discovery programmes.

The numbers speak for themselves. Drugs developed with genetic data support are two to three times more likely to succeed in clinical trials. This offers a game-changing advantage in accelerating therapeutic innovation, reducing risks and costs for the company’s partners, and making personalised medicine accessible to more people.

When engaging with a new client, Genomics’ priority is to understand their needs and identify where genomic data can be effectively applied to solve specific requirements. These needs often vary significantly from one pharmaceutical partner to another. From there, it steps back, develops a tailored proposal and creates a strategy to help them—whether optimising clinical trial designs or enhancing portfolio management.

The driving force behind Genomics’ success is its team of world-class scientists, whose unmatched expertise is backed by over a decade of experience. The team’s deep domain knowledge, honed through years of successful partnerships, empowers pharmaceutical companies to be a trusted ally for pharmaceutical companies navigating the complexities of drug discovery and development.

Looking ahead, Genomics envisions a world transformed by the power of genome mapping—a world where healthcare isn’t just reactive but predictive, personal and precise. With technology as its backbone, world-class expertise as its compass and an unyielding drive for innovation, it is redefining the art of drug discovery and revolutionising the healthcare landscape.